Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We speculated that the mutation D151N in LPL gene might be associated with FCHL and early-onset coronary heart disease in this family.
|
31599081 |
2020 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Despite these differences in associated lipid levels, the LPL and LDLR scores were associated with similar lower risk of CHD per 10-mg/dL lower level of ApoB-containing lipoproteins (OR, 0.771 [95% CI, 0.741-0.802], P = 3.9 × 10-38 and OR, 0.773 [95% CI, 0.747-0.801], P = 1.1 × 10-46, respectively).
|
30694319 |
2019 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To investigate the independent and combined associations of genetically determined differences in LPL-mediated lipolysis and low-density lipoprotein cholesterol (LDL-C) metabolism with risk of coronary disease and diabetes.
|
30326043 |
2018 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The LPL polymorphism contributed to the severity of coronary disease in patients with MS and recent ACS.
|
29412239 |
2018 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Hyperlipidemia is a risk factor of arteriosclerosis, stroke, and other coronary heart disease, which has been shown to correlate with single nucleotide polymorphisms of genes essential for lipid metabolism, such as lipoprotein lipase (LPL) and apolipoprotein A5 (APOA5).
|
29425239 |
2018 |
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The role of plasma lipoprotein lipase, hepatic lipase and GPIHBP1 in the metabolism of remnant lipoproteins and small dense LDL in patients with coronary artery disease.
|
29174344 |
2018 |
Coronary heart disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
While exposing the polygenic architecture of circulating lipids and the underpinnings of dyslipidaemia, these genome-wide association studies (GWAS) have provided further evidence of the critical role that lipids play in coronary heart disease (CHD) risk, as indicated by the 2.7-fold enrichment for macrophage gene expression in atherosclerotic plaques and the association of 25 loci (such as PCSK9, APOB, ABCG5-G8, KCNK5, LPL, HMGCR, NPC1L1, CETP, TRIB1, ABO, PMAIP1-MC4R, and LDLR) with CHD.
|
29800275 |
2018 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The presence of rare damaging mutations in LPL was significantly associated with higher triglyceride levels and presence of coronary artery disease.
|
28267856 |
2017 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Lipoprotein Lipase (LPL) Polymorphism and the Risk of Coronary Artery Disease: A Meta-Analysis.
|
28275220 |
2017 |
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
RGD |
Effect of DanQi Pill on PPARα, lipid disorders and arachidonic acid pathway in rat model of coronary heart disease.
|
27000070 |
2016 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Study of common variants of the apolipoprotein E and lipoprotein lipase genes in patients with coronary heart disease and variable body mass index.
|
26188224 |
2016 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
ANGPTL4 inhibits lipoprotein lipase; we therefore searched for mutations in LPL and identified a loss-of-function variant that was associated with an increased risk of coronary artery disease (p.D36N; minor-allele frequency, 1.9%; odds ratio, 1.13; P=2.0×10(-4)) and a gain-of-function variant that was associated with protection from coronary artery disease (p.S447*; minor-allele frequency, 9.9%; odds ratio, 0.94; P=2.5×10(-7)).
|
26934567 |
2016 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
GWASCAT |
Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis of common variants.
|
24262325 |
2014 |
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
There are limited data from prospective studies regarding interactions between lipoprotein lipase gene (LPL) and lifestyle factors in association with HDL-cholesterol (HDL-C) concentrations, a biomarker of coronary heart disease risk.
|
23902956 |
2013 |
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Synergistic effect between lipoprotein lipase and apolipoprotein C3 genes in determining the severity of coronary artery disease.
|
23377670 |
2013 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
DNA polymorphisms of the lipoprotein lipase gene and their association with coronary artery disease in the Saudi population.
|
22837712 |
2012 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
LPL polymorphisms' effects on lipids and coronary artery disease are controversial among studies and populations.
|
22729917 |
2012 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Among the 20 blood lipid-related SNPs, LPL rs17411031 was associated with a lower risk of CHD (OR 0.91; 0.84-0.97), an increase in Apolipoprotein AI and HDL-cholesterol, and reduced triglycerides.
|
21804106 |
2012 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association study of coronary heart disease and its risk factors in 8,090 African Americans: the NHLBI CARe Project.
|
21347282 |
2011 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The S447X variant of lipoprotein lipase gene is inversely associated with severity of coronary artery disease.
|
21127884 |
2011 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Nine loci were statistically associated with incident CHD events in white participants: 9p21 (rs10757278; P=4.7 × 10(-41)), 16q23.1 (rs2549513; P=0.0004), 6p24.1 (rs499818; P=0.0002), 2q36.3 (rs2943634; P=6.7 × 10(-6)), MTHFD1L (rs6922269, P=5.1 × 10(-10)), APOE (rs429358; P=2.7×10(-18)), ZNF627 (rs4804611; P=5.0 × 10(-8)), CXCL12 (rs501120; P=1.4 × 10(-6)) and LPL (rs268; P=2.7 × 10(-17)).
|
22042884 |
2011 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This suggests that the LIPC -514C>T variant significantly affects training-induced anti-atherogenic changes in VLDL-TG, VLDL particles, and HDL through an association with increased LPL activity in CC subjects, which could guide therapeutic strategies to reduce CHD risk.
|
21960661 |
2011 |
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Associations for lipoprotein lipase and peroxisome proliferator-activated receptor-gamma gene and coronary artery disease in an Indian population.
|
20430250 |
2010 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Associations of lipoprotein lipase S447X and apolipoprotein E genotypes with low-density lipoprotein subfractions in Turkish patients with coronary artery disease.
|
19368142 |
2009 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The LPL S447X variant tended to be associated with lower TG and higher HDL-C levels, and lower risk of CHD in all 3 cohorts.
|
19185650 |
2009 |